Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study

Daphne T Adelman,1 Andrea Burgess,2 Philippa R Davies,31Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; 2Neuroendocrine Tumor Department, The Christie, Manchester, UK; 3Neuroendocrine Tumor Unit, Royal Free Hospital, London, UKAbstract: The somatostatin analogs (SSAs) lanreot...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Adelman DT, Burgess A, Davies PR
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Medical technology R855-855.5
Acceso en línea:	https://doaj.org/article/9ecc58596e764d0f83610329d0c37beb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9ecc58596e764d0f83610329d0c37beb
record_format	dspace
spelling	oai:doaj.org-article:9ecc58596e764d0f83610329d0c37beb2021-12-02T08:43:42ZEvaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study1179-1470https://doaj.org/article/9ecc58596e764d0f83610329d0c37beb2012-12-01T00:00:00Zhttp://www.dovepress.com/evaluation-of-long-acting-somatostatin-analog-injection-devices-by-nur-a11753https://doaj.org/toc/1179-1470Daphne T Adelman,1 Andrea Burgess,2 Philippa R Davies,31Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; 2Neuroendocrine Tumor Department, The Christie, Manchester, UK; 3Neuroendocrine Tumor Unit, Royal Free Hospital, London, UKAbstract: The somatostatin analogs (SSAs) lanreotide Autogel/Depot and octreotide long-acting release are used to treat acromegaly and neuroendocrine tumors. The present study evaluated opinions on SSA injection devices, including a recently approved lanreotide new device (lanreotide-ND), among nurses in Europe and the USA. Nurses injecting SSAs for at least three patients per year (n = 77) were interviewed regarding SSA devices. Device attributes were rated via questionnaire; nurses were then timed administering test injections with lanreotide-ND and octreotide long-acting release. The most important delivery system attributes were easy/convenient preparation and injection (ranked in the top five by 70% of nurses), low clogging risk (58%), and high product efficacy (55%). Compared with the octreotide long-acting release device, lanreotide-ND scored higher on 15/16 attributes, had shorter mean preparation and administration time (329 versus 66 seconds, respectively; P &le; 0.01) and a higher overall preference score (70 versus 114, respectively; P &le; 0.01). The five most important lanreotide-ND attributes were: prefilled device, confidence a full dose was delivered, low clogging risk, easy/convenient preparation and injection, and fast administration. These device features could lead to improvements in clinical practice and benefit patients/caregivers who administer SSAs at home.Keywords: nurse, somatostatin analog, device, lanreotide, octreotideAdelman DTBurgess ADavies PRDove Medical PressarticleMedical technologyR855-855.5ENMedical Devices: Evidence and Research, Vol 2012, Iss default, Pp 103-109 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medical technology R855-855.5
spellingShingle	Medical technology R855-855.5 Adelman DT Burgess A Davies PR Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study
description	Daphne T Adelman,1 Andrea Burgess,2 Philippa R Davies,31Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; 2Neuroendocrine Tumor Department, The Christie, Manchester, UK; 3Neuroendocrine Tumor Unit, Royal Free Hospital, London, UKAbstract: The somatostatin analogs (SSAs) lanreotide Autogel/Depot and octreotide long-acting release are used to treat acromegaly and neuroendocrine tumors. The present study evaluated opinions on SSA injection devices, including a recently approved lanreotide new device (lanreotide-ND), among nurses in Europe and the USA. Nurses injecting SSAs for at least three patients per year (n = 77) were interviewed regarding SSA devices. Device attributes were rated via questionnaire; nurses were then timed administering test injections with lanreotide-ND and octreotide long-acting release. The most important delivery system attributes were easy/convenient preparation and injection (ranked in the top five by 70% of nurses), low clogging risk (58%), and high product efficacy (55%). Compared with the octreotide long-acting release device, lanreotide-ND scored higher on 15/16 attributes, had shorter mean preparation and administration time (329 versus 66 seconds, respectively; P &le; 0.01) and a higher overall preference score (70 versus 114, respectively; P &le; 0.01). The five most important lanreotide-ND attributes were: prefilled device, confidence a full dose was delivered, low clogging risk, easy/convenient preparation and injection, and fast administration. These device features could lead to improvements in clinical practice and benefit patients/caregivers who administer SSAs at home.Keywords: nurse, somatostatin analog, device, lanreotide, octreotide
format	article
author	Adelman DT Burgess A Davies PR
author_facet	Adelman DT Burgess A Davies PR
author_sort	Adelman DT
title	Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study
title_short	Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study
title_full	Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study
title_fullStr	Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study
title_full_unstemmed	Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study
title_sort	evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/9ecc58596e764d0f83610329d0c37beb
work_keys_str_mv	AT adelmandt evaluationoflongactingsomatostatinanaloginjectiondevicesbynursesaquantitativestudy AT burgessa evaluationoflongactingsomatostatinanaloginjectiondevicesbynursesaquantitativestudy AT daviespr evaluationoflongactingsomatostatinanaloginjectiondevicesbynursesaquantitativestudy
_version_	1718398428526936064

Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study

Ejemplares similares